EPRX logo

EPRX
Eupraxia Pharmaceuticals Inc

152
Mkt Cap
$440.98M
Volume
259,637.00
52W High
$9.32
52W Low
$2.68
PE Ratio
-7.23
EPRX Fundamentals
Price
$7.17
Prev Close
$7.33
Open
$7.13
50D MA
$7.97
Beta
0.61
Avg. Volume
231,875.53
EPS (Annual)
-$1.03
P/B
7.12
$248.55
Loading...
Loading...
News
all
press releases
New Strong Sell Stocks for April 2nd
ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.
Zacks·22h ago
News Placeholder
More News
News Placeholder
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,500,950 shares, an increase of 26.3% from the February 26th total of 1,979,996 shares. Approximately...
MarketBeat·4d ago
News Placeholder
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday
Eupraxia Pharmaceuticals (NASDAQ:EPRX) will be releasing earnings before the market opens on Tuesday, March 31. (View Earnings Report at...
MarketBeat·10d ago
News Placeholder
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.read more...
Benzinga·11d ago
News Placeholder
William Blair Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)
William Blair assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday. They issued an "outperform" rating for the company...
MarketBeat·11d ago
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21...
MarketBeat·15d ago
News Placeholder
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Zacks Research
Zacks Research downgraded Eupraxia Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday...
MarketBeat·15d ago
News Placeholder
Lifesci Capital Has Negative Outlook of EPRX FY2026 Earnings
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Analysts at Lifesci Capital dropped their FY2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research note issued to investors on Monday, March 16th. Lifesci Capital analyst S. Slutsky now forecasts that the com...
MarketBeat·15d ago
News Placeholder
What is HC Wainwright's Estimate for EPRX Q1 Earnings?
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 17th. HC Wainwright analyst B. Folkes forecasts that t...
MarketBeat·15d ago
News Placeholder
Q2 Earnings Estimate for EPRX Issued By HC Wainwright
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Eupraxia Pharmaceuticals in a report released on...
MarketBeat·16d ago
<
1
2
...
>

Latest EPRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.